More importantly, treatment with irbesartan remarkably attenuated ACE2-dificiency induced myocardial hypertrophy and ultrastructure injury along with augmentation of cardiac PPARγ level, without having a differential effect on the expression of PPARα and PPARδ. The gene discussed is ACE2; the disease is cardiac hypertrophy.